Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This research study is being conducted in the U.S. and Europe to evaluate the safety and
efficacy of daclizumab for the treatment of multiple sclerosis (MS).
Phase:
Phase 2
Details
Lead Sponsor:
PDL BioPharma, Inc.
Treatments:
Antibodies Antibodies, Monoclonal Daclizumab Immunoglobulin G